PROFILPELAJAR.COM

TNFRSF8
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	1D01
Identifiers
Aliases	TNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8, TNF receptor superfamily member 8
External IDs	OMIM: 153243; MGI: 99908; HomoloGene: 949; GeneCards: TNFRSF8; OMA:TNFRSF8 - orthologs
Gene location (Human)
Chr.	Chromosome 1 (human)
End	12,144,207 bp
Gene location (Mouse)
Chr.	Chromosome 4 (mouse)
End	145,041,734 bp
RNA expression pattern
	Top expressed in
	granulocyte; ; monocyte; ; testicle; ; blood; ; pancreatic ductal cell; ; decidua; ; subcutaneous adipose tissue; ; periodontal fiber; ; appendix; ; right auricle;
	Top expressed in
	neural layer of retina; ; blastocyst; ; secondary oocyte; ; embryo; ; zygote; ; morula; ; embryo; ; thymus; ; dentate gyrus of hippocampal formation granule cell; ; primary oocyte;
	More reference expression data
	More reference expression data
Gene ontology
Molecular function	transmembrane signaling receptor activity; tumor necrosis factor-activated receptor activity; nerve growth factor binding;
Cellular component	cytoplasm; integral component of membrane; integral component of plasma membrane; extracellular exosome; membrane; plasma membrane; nucleus; neuron projection;
Biological process	apoptotic signaling pathway; cellular response to mechanical stimulus; response to lipopolysaccharide; inflammatory response; immune response; signal transduction; negative regulation of cell population proliferation; positive regulation of apoptotic process; tumor necrosis factor-mediated signaling pathway; axon guidance; negative regulation of neuron projection development; positive regulation of NF-kappaB transcription factor activity;
	Sources:Amigo / QuickGO
Orthologs
	943
	21941
	ENSG00000120949
	ENSMUSG00000028602
	P28908
	Q60846
	NM_001243; NM_001281430; NM_152942
	NM_009401
	NP_001234; NP_001268359
	NP_033427
	Wikidata
View/Edit Human	View/Edit Mouse

CD30, also known as TNFRSF8 (TNF receptor superfamily member 8),^[5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker.

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB.^[6] It is a positive regulator of apoptosis,^[7] and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.^{[citation needed]} Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.^[5]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.^[8] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.^[9]

Cancer treatment

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen^[10]
Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy^[11]
Various types of CD30-positive T cell lymphomas^[12]

Brentuximab vedotin is also currently being studied in and recommended for treating:

Various types of CD30-positive B cell lymphomas^[13]
CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type^[14]

Interactions

CD30 has been shown to interact with TRAF5,^[6] and TRAF2.^[6]^[7]

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000120949 – Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000028602 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ ^a ^b "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily member 8". National Library of Medicine, National Center for Biotechnology Information. 22 September 2022. Retrieved 6 November 2022.
^ ^a ^b ^c Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–2045. doi:10.1074/jbc.272.4.2042. PMID 8999898.
^ ^a ^b Duckett CS, Thompson CB (November 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development. 11 (21): 2810–2821. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.
^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese). 34 (11): 711–5. PMID 16536313.
^ Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.
^ Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research. 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.
^ "FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma". FDA.gov. Retrieved March 2, 2018.
^ "FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot". FDA.gov. 24 March 2020. Retrieved December 13, 2023.
^ Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F (January 2017). "Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review". Critical Reviews in Oncology/Hematology. 109: 42–50. doi:10.1016/j.critrevonc.2016.11.009. PMC 5218629. PMID 28010897.
^ Hu B, Oki Y (2018). "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma". Frontiers in Oncology. 8: 139. doi:10.3389/fonc.2018.00139. PMC 5937056. PMID 29761078.

External links

CD30+Antigens at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Human TNFRSF8 genome location and TNFRSF8 gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000120949 – Ensembl, May 2017

[refGRCm38Ensembl-2] GRCm38: Ensembl release 89: ENSMUSG00000028602 – Ensembl, May 2017

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[entrez-5] "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily member 8". National Library of Medicine, National Center for Biotechnology Information. 22 September 2022. Retrieved 6 November 2022.

[pmid8999898-6] Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–2045. doi:10.1074/jbc.272.4.2042. PMID 8999898.

[pmid9353251-7] Duckett CS, Thompson CB (November 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development. 11 (21): 2810–2821. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.

[8] Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese). 34 (11): 711–5. PMID 16536313.

[9] Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.

[10] Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research. 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.

[11] "FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma". FDA.gov. Retrieved March 2, 2018.

[12] "FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot". FDA.gov. 24 March 2020. Retrieved December 13, 2023.

[pmid28010897-13] Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F (January 2017). "Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review". Critical Reviews in Oncology/Hematology. 109: 42–50. doi:10.1016/j.critrevonc.2016.11.009. PMC 5218629. PMID 28010897.

[pmid29761078-14] Hu B, Oki Y (2018). "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma". Frontiers in Oncology. 8: 139. doi:10.3389/fonc.2018.00139. PMC 5937056. PMID 29761078.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

PROFILPELAJAR.COM

CD30

Function

Clinical significance

Cancer treatment

Interactions

References

Further reading

External links

Read other articles:

El río que nos lleva (película)

Putih uban

Farø

Pertempuran Makau

Daftar katedral di Siprus

Yalgoo bioregion

Felice di Thibiuca

大字 (数字)

Oyne

بنك الجنوب (أمريكا اللاتينية)

Abram Hewitt

Fez (hat)

Tepotzotlán

Ayub 39

Летние юношеские Олимпийские игры 2018

Campionato mondiale di Formula 1 1993

Keuskupan Asansol

Abetone Cutigliano

柏林圍牆

Srédéts (Bourgas)